Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study

Egle, Alexander; Steurer, Michael; Melchardt, Thomas; Weiss, Lukas; Gassner, Franz Josef; Zaborsky, Nadja; Geisberger, Roland; Catakovic, Kemal; Hartmann, Tanja Nicole; Pleyer, Lisa; Voskova, Daniela; Thaler, Josef; Lang, Alois; Girschikofsky, Michael; Petzer, Andreas; Greil, Richard

doi:10.1007/s00277-018-3403-9

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study

Correction
Published: 23 June 2018

Volume 97, page 1745, (2018)
Cite this article

Download PDF

Annals of Hematology Aims and scope Submit manuscript

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study

Download PDF

Alexander Egle^1,2,
Michael Steurer³,
Thomas Melchardt^1,2,
Lukas Weiss^1,2,
Franz Josef Gassner²,
Nadja Zaborsky²,
Roland Geisberger²,
Kemal Catakovic²,
Tanja Nicole Hartmann²,
Lisa Pleyer^1,2,
Daniela Voskova⁴,
Josef Thaler⁵,
Alois Lang⁶,
Michael Girschikofsky⁷,
Andreas Petzer⁸ &
…
Richard Greil^1,2

1289 Accesses
1 Citation
Explore all metrics

The Original Article was published on 04 June 2018

Correction to: Annals of Hematology

https://doi.org/10.1007/s00277-018-3380-z

The original version of this article contained a mistake. The name of Tanja Nicole Hartman should have been Tanja Nicole Hartmann.

The original article has been corrected.

Author information

Authors and Affiliations

Department of Internal Medicine III with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Müllner-Hauptstr. 48, 5020, Salzburg, Austria
Alexander Egle, Thomas Melchardt, Lukas Weiss, Lisa Pleyer & Richard Greil
Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and Cancer Cluster Salzburg (CCS), Salzburg, Austria
Alexander Egle, Thomas Melchardt, Lukas Weiss, Franz Josef Gassner, Nadja Zaborsky, Roland Geisberger, Kemal Catakovic, Tanja Nicole Hartmann, Lisa Pleyer & Richard Greil
Division of Hematology and Oncology, Laboratory for Molecular Genetics and Diagnostics, Innsbruck Medical University, Innsbruck, Austria
Michael Steurer
Centre for Hematology and Medical Oncology, Kepler University Hospital, Linz, Austria
Daniela Voskova
Department for Internal Medicine IV, Hospital Wels-Grieskirchen, Wels, Austria
Josef Thaler
Internal Medicine, Hospital, Feldkirch, Austria
Alois Lang
Internal Medicine I (Hemostasis, Hematology and Stem Cell Transplantation and Medical Oncology), Ordensklinikum Linz Elisabethinen, Linz, Austria
Michael Girschikofsky
Department for Internal Medicine IV, Hospital Barmherzige Schwestern Linz, Linz, Austria
Andreas Petzer

Authors

Alexander Egle
View author publications
You can also search for this author in PubMed Google Scholar
Michael Steurer
View author publications
You can also search for this author in PubMed Google Scholar
Thomas Melchardt
View author publications
You can also search for this author in PubMed Google Scholar
Lukas Weiss
View author publications
You can also search for this author in PubMed Google Scholar
Franz Josef Gassner
View author publications
You can also search for this author in PubMed Google Scholar
Nadja Zaborsky
View author publications
You can also search for this author in PubMed Google Scholar
Roland Geisberger
View author publications
You can also search for this author in PubMed Google Scholar
Kemal Catakovic
View author publications
You can also search for this author in PubMed Google Scholar
Tanja Nicole Hartmann
View author publications
You can also search for this author in PubMed Google Scholar
Lisa Pleyer
View author publications
You can also search for this author in PubMed Google Scholar
Daniela Voskova
View author publications
You can also search for this author in PubMed Google Scholar
Josef Thaler
View author publications
You can also search for this author in PubMed Google Scholar
Alois Lang
View author publications
You can also search for this author in PubMed Google Scholar
Michael Girschikofsky
View author publications
You can also search for this author in PubMed Google Scholar
Andreas Petzer
View author publications
You can also search for this author in PubMed Google Scholar
Richard Greil
View author publications
You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard Greil.

Additional information

The online version of the original article can be found at https://doi.org/10.1007/s00277-018-3380-z

Rights and permissions

Reprints and permissions

About this article

Cite this article

Egle, A., Steurer, M., Melchardt, T. et al. Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study. Ann Hematol 97, 1745 (2018). https://doi.org/10.1007/s00277-018-3403-9

Download citation

Published: 23 June 2018
Issue Date: September 2018
DOI: https://doi.org/10.1007/s00277-018-3403-9

Use our pre-submission checklist

Avoid common mistakes on your manuscript.

Correction to: Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study

Author information

Authors and Affiliations

Corresponding author

Additional information

Rights and permissions

About this article

Cite this article

Share this article

Search

Navigation